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Abstract
Infantile myofibromatosis (IM), which is typically diagnosed in young children, comprises a wide clinical spectrum ranging 
from inconspicuous solitary soft tissue nodules to multiple disseminated tumors resulting in life-threatening complications. 
Familial IM follows an autosomal dominant mode of inheritance and is linked to PDGFRB germline variants. Somatic 
PDGFRB variants were also detected in solitary and multifocal IM lesions. PDGFRB variants associated with IM consti-
tutively activate PDGFRB kinase activity in the absence of its ligand. Germline variants have lower activating capabilities 
than somatic variants and, thus, require a second cis-acting hit for full receptor activation. Typically, these mutant receptors 
remain sensitive to tyrosine kinase inhibitors such as imatinib. The SIOPE Host Genome Working Group, consisting of 
pediatric oncologists, clinical geneticists and scientists, met in January 2020 to discuss recommendations for genetic test-
ing and surveillance for patients who are diagnosed with IM or have a family history of IM/PDGFRB germline variants. 
This report provides a brief review of the clinical manifestations and genetics of IM and summarizes our interdisciplinary 
recommendations.
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Introduction
Infantile myofibromatosis/myofibromas (IM) were first 
described by Stout in 1954 as congenital generalized 
fibromatosis [1]. Disease manifestations range from solitary 
soft tissue nodules (infantile myofibromas) to multiple or 
disseminated (generalized) tumors (infantile myofibroma-
tosis) with life-threatening complications, particularly if 
visceral disease is present. Most IM cases are diagnosed 
in children below 2 years of age. The reported incidence 
of IM is 1 in 150,000 live births, but, as minor forms of the 
disease may go unnoticed, the true incidence of IM is likely 
much higher [2].
Clinical case presentation
A female infant, born at 38 + 3 weeks gestation by vagi-
nal delivery to a 27 year-old healthy mother, presented 
with a large round mass on the left forefoot and a 9 mm 
red-colored lesion on the lateral aspect of the right hand at 
birth (Fig. 1a, b). Prenatal screening had not revealed any 
anomalies. Whole body MRI was carried out on day of life 
4 and demonstrated contrast-enhancing lesions in the chest 
(2.6 × 2.4 × 1.4 cm, located in the left paracardial region with 
direct contact to the thymus, Fig. 1e), on the left foot, right 
hand and left-sided rectus femoris muscle. High resolution 
MRI of the left foot revealed a 4.3 × 4.2 × 2.4 cm mass on the 
left forefoot with bony involvement, complete enclosure of 
the 5th toe, 180° enclosure of the 4th toe and partial necrosis 
(Fig. 1f, g). Open incisional biopsies of the lesions on the 
left forefoot and right hand were carried out on day 5 of life. 
Histology was consistent with IM. It was decided to take a 
wait-and-see approach. The child developed new tumors on 
the left temporal aspect of the head and the left thigh within 
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35 days, but the mass on the left forefoot continued to shrink 
(Fig. 1a, d, g–i), the lesion on the right hand disappeared 
completely, and the intrathoracic tumor remained stable 
without signs of progression. The child was 1.5 months old 
at the time of this report and clinically well with persistent 
lesions on the head, thigh, left foot and in the chest. Of note, 
the child’s older sister had presented with a right cervical 
mass at the age of 5 weeks. At 2 months of age, an additional 
mass developed on the left thigh. Both tumors were removed 
by incisional biopsies and consistent with myofibromas. The 
sister’s subsequent clinical course was uneventful. Taken 
together, these two cases illustrate familial manifestation of 
IM with multifocal lesions, including a paracardial mass in 
the younger sister, within the first month of life. Written 
informed consent regarding this report was obtained from 
the parents.
PDGFRB variants in infantile myofibromatosis
Germline variants
Variants in the platelet-derived growth factor receptor-beta 
(PDGFRB) gene were initially discovered in families with 
autosomal-dominantly inherited IM [3, 4]. At least 20 fami-
lies have been reported so far, 19 of which carry a heterozy-
gous PDGFRB variant (NM_002609.4): p.Arg561Cys in 15 
(79%) of these 19 cases. The same variant was also reported 
in sporadic cases of IM [5–7]. Three families carry unique 
PDGFRB germline variants that are classified as likely 
pathogenic: p.Pro560Leu, p.Arg561Ser, and p.Lys567Glu 
[8–10]. All these variants cluster in the juxtamembrane 
domain of the receptor, encoded by exon 12. One family had 
a p.Pro660Thr variant of uncertain significance in the kinase 
domain, encoded by exon 14 [4, 11]. In one family with wild 
type PDGFRB, a heterozygous NOTCH3 variant of uncer-
tain significance (i.e., NM_000435.2: p.Leu1519Pro) was 
reported [4].
To our best knowledge, 44 individuals were reported in 
the literature to carry a germline PDGFRB variant [3–6, 8-
10, 12–14]. Clinical information is available on 36 of these 
44 individuals (Table 1). The phenotype of individuals 
within the same family may vary considerably, from asymp-
tomatic carriers to lethal generalized IM [10, 14]. Four out 
of 36 (11%) PDGFRB variant carriers, whose clinical course 
was described in the literature, were IM-free (Table 1). Yet, 
incomplete penetrance remains difficult to quantify because 
benign isolated nodules may go unnoticed and regress 
spontaneously in childhood [10, 13]. Three out of 36 (8%) 
PDGFRB variant carriers developed solitary IM, 29 (81%) 
were diagnosed with multicentric or generalized disease, 
and 2 (6%) died. Data on age at diagnosis are incomplete, 
but the majority of PDGFRB germline variant carriers were 
Fig. 1  Familial IM manifesting with multifocal lesions at birth. a 
Large tumor on left forefoot immediately after birth. b Mass on 
right hand immediately after birth. c Necrosis of the tumor on the 
left forefoot on day of life 5. d Further shrinkage of the tumor on the 
left forefoot on day of life 30. e Left paracardial mass and f, g large 
tumor on left forefoot depicted by whole body MRI on day of life 4. 
g, i Shrinkage of the tumor on the left forefoot as illustrated by serial 
MRI imaging on g day of life 4, h day of life 6 and i day of life 26
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diagnosed with IM during infancy/early childhood. There 
was at least one case of congenital IM (diagnosed during the 
first month of life) in 7 of 13 families (Table 1).
Somatic variants
In the largest series of sporadic cases analyzed so far, 
Dachy and colleagues found somatic PDGFRB variants in 
68% of IM and 29% of isolated solitary pediatric IM [7]. In 
multicentric disease, the same post-zygotic variant can be 
found in different nodules that develop independently in the 
same patient, suggesting constitutional mosaicism. In about 
half of the cases, PDGFRB contains double mono-allelic 
variants: a first one in exon 12, which may be germline or 
somatic, is associated with a second one in exon 14, such as 
p.Asn666Lys [3, 7, 15, 16]. RNA analysis revealed that the 
two variants are located on the same allele, the other allele 
being wild type [15]. This is reminiscent of the pathogenic 
variants found in another receptor tyrosine kinase gene, 
TIE2, in venous malformations [17]. Finally, a complex 
somatic/mosaic PDGFRB re-arrangement with an apparent 
partial tandem duplication involving the juxtamembrane 
domain and resulting in MAPK activation was recently 
detected in a newborn with multicentric IM [18].
Functional impact
Appropriate signaling though PDGFRB is essential for a 
variety of cells such as radial glia, renal glomerular cells as 
well as for pericytes, which are the proposed cells of ori-
gin of IM. PDGFRB variants associated with IM constitu-
tively activate PDGFRB receptor kinase activity [11]. Most 
variants are located within the juxtamembrane domain or 
in the kinase domain, the function of which is to prevent 
inappropriate activation of the kinase. Nevertheless, patho-
genic variants are also found in the extracellular and trans-
membrane domains of the receptor. Interestingly, germline 
variants cluster in the juxtamembrane domain (Fig. 2). Their 
constitutive activation capabilities are weaker than those of 
somatic variants, and double mutant alleles frequently dis-
played additive activation in reporter assays, thus indicat-
ing the cooperating effects of germline and somatic variants 
affecting the same allele [15].
Imatinib sensitivity
Imatinib is a potent inhibitor of the kinase domain of PDGF 
receptors. This drug was approved for the treatment of mul-
tiple neoplasms associated with aberrant PDGF receptor 
activation, including dermatofibrosarcoma protuberans, gas-
trointestinal stromal tumors, a subset of acute lymphoblastic 
leukemia, and myeloid neoplasms with hypereosinophilia 
Table 1  PDGFRB germline variants in families with heritable IM reported in the literature
No of number of, w/ with, IM infantile myofibromatosis,
a Martignetti et al. reported 7 more families with p.Arg561Cys PDGFRB variants and 1 family with a p.Pro660Thr PDGFRB variant and IM 
without providing further clinical information. We included two isolated germline cases without familial history
b Information on age at diagnosis of IM is available on a subset of patients only
c This column includes cases that were not genotyped
Familya References PDGFRB variant No. of family 
members with 
 IMc
No. of PDGFRB variant carriers per family Age at 
diagnosis 








1 [3] p.Arg561Cys 3 3 1 2 0 0 6–48 mo
2 [3] p.Arg561Cys 2 2 0 2 0 0  < 12 mo
3 [3] p.Arg561Cys 3 3 0 3 0 0  < 48 mo
4 [3] p.Arg561Cys 3 3 0 3 0 0 1–7 mo
5 [13] p.Arg561Cys 2 3 0 2 1 0 0–5 mo
6 [9] p.Pro560Leu 6 5 0 4 1 0  < 1mo
7 [10] p.Lys567Glu 5 6 1 4 1 1 0–12 mo
8 [10] p.Arg561Cys 3 3 1 2 0 0 0–14 mo
9 [8] p.Arg561Ser 3 2 0 2 0 0 0–12 mo
10 [12] p.Arg561Cys 9 2 0 2 0 0 0-12mo
11 [14] p.Arg561Cys 1 2 0 1 1 1  < 1 mo
12 [6] p.Arg561Cys 1 1 0 1 0 0  < 25 mo
13 [5] p.Arg561Cys 1 1 0 1 0 0 19 yo
Total 42 36 3 29 4 2
330 S. Hettmer et al.
1 3
[19]. Most of the mutants identified in IM are highly sensi-
tive to imatinib in vitro [7]. Only one variant, p.Asp850Val, 
confers full resistance to this compound, suggesting that 
most patients with PDGFRB-mutant IM may be eligible for 
imatinib therapy. Two case reports suggest that this drug 
is effective and well tolerated [5, 20]. Side effects include 
growth retardation, as reported in children with chronic 
myeloid leukemia treated with imatinib [21].
Genetically related disorders 
with and without myofibroma susceptibility
The clinical phenotype associated with PDGFRB germline 
variants is variable (Fig. 2). Germline PDGFRB mutations 
can also cause other congenital diseases, including Kosaki 
overgrowth syndrome (OMIM 616592) and Penttinen 
syndrome (OMIM 601812), reported in a small number of 
patients. Germline gain-of-function variants associated with 
these conditions activate PDGFRB more potently than those 
found in familial IM [11].
Kosaki overgrowth syndrome is associated with tall 
stature, dysmorphic facial features, hyperelastic skin, and 
progressive neurological deterioration, mostly associated 
with white matter changes [22, 23]. The clinical features of 
Kosaki overgrowth syndrome include myofibromas. Patients 
with Penttinen syndrome exhibit premature aging, lipoatro-
phy, dermal atrophy, and thin hair [24, 25]. PDGFRB muta-
tions associated with mixed phenotypes were reported [20, 
26].
Somatic/mosaic activating variants within the juxtam-
embrane domain or the kinase activation loop were also 
described in 4 out of 6 patients with fusiform cerebral 
Fig. 2  PDGFRB variants in 
infantile myofibromatosis and 
other diseases. The location of 
all germline and most signifi-
cant somatic/mosaic variants 
of PDGFRB is indicated, with 
the corresponding exons in 
dark grey (NM_002609.4). 
Orange and red dots depict IM 
mutations that are somatic/
mosaic and germline, respec-
tively. Purple dots correspond 
to gain-of-function mutations 
found in other diseases (Kosaki 
overgrowth, Penttinen, and 
related syndromes). Double dots 
indicate recurrent mutations. 
“Indel” indicates the position 
of reported small in-frame 
insertions and deletions. X 
denotes that several amino-acid 
substitutions were reported at 
the indicated position. Loss-
of-function mutations associ-
ated with Fahr disease are not 
shown. D1 to D5: extracellular 
Ig-like domains of the receptor
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aneurysms [27]. In fact, recent studies suggest that aneu-
rysms may be common in patients with germline PDGFRB 
variants (e.g. p.Trp566Arg, p.Ser493Cys) and cause severe 
complications, including sudden death [15, 28–30]. Aneu-
rysms were also reported in a sporadic IM case [15].
Finally, heterozygous loss-of-function variants of PDG-
FRB, among other genes, have been associated with primary 
familial brain calcification (also named idiopathic basal 
ganglia calcification 4 or Fahr disease, OMIM 615007). 
This condition features a bilateral calcification of the basal 
ganglia, and neurological symptoms developing throughout 
life, including Parkinsonism, impaired cognitive function, 
migraine, and depression [31].
Other genes in infantile myofibromatosis
Martignetti and colleagues identified a germline NOTCH3 
variant in all affected individuals of a single family with IM 
[4]. However, functional characterization of the variant is 
still lacking and germline NOTCH3 variants have not been 
reported in other families or patients with IM. Using RNA 
sequencing of tumor samples, Antonescu and colleagues 
reported somatic serum-response factor (SRF) fusion genes 
in IM, including SRF-RELA [32]. SRF encodes a transcrip-
tion factor that is controlled by mitogen signaling path-
ways, downstream PDGF receptors, and has been shown to 
be involved in murine heart and vascular smooth muscle 
cell development [32]. Future studies should address the 
functional consequences of SRF fusion genes and establish 
whether SRF fusions and PDGFRB alterations are mutually 
exclusive.
Brief review of the current literature
Infantile myofibromatosis
Clinical manifestation
IM commonly presents with firm, non-tender, flesh-colored 
nodules, which may arise in any body region. IM lesions 
are most commonly located in the skin, subcutaneous tis-
sue or muscle of the head, neck, and trunk. Superficially 
located nodules are often noted by parents and caregivers 
and are non-ulcerative. Deep-seated foci are either detected 
by imaging following recognition of superficial lesions or 
through their symptomatology. Up to 74% of all IM cases are 
detected shortly after birth; 89% of IM cases are diagnosed 
within the first two years of life [33]. Rare first presenta-
tions of IM in older children and adults have been reported 
in the literature [5]. IM presents with one of three clini-
cal patterns: solitary (50 to 74% of all cases), multicentric, 
and generalized (with visceral involvement) manifestations. 
Skeletal lesions are common in children with multicentric 
IM (approximately 75% of cases [2, 34, 35]). Multicentric 
IM may present with or without visceral involvement. Vis-
ceral IM lesions have been observed in 11 to 19% of cases 
[2, 33, 36]. Visceral lesions typically involve the cardio-
pulmonary and/or gastrointestinal system. Intracranial (both 
intra- and extra-axial) involvement has been seen occasion-
ally [37]. Familial IM cases follow an autosomal-dominant 
mode of inheritance, and often present with early-onset mul-
ticentric lesions [2, 3].
Diagnosis
Histopathologically, tumors are nodular and composed of 
myoid spindle-shaped cells with pink cytoplasm and elon-
gated nuclei without atypia, arranged in a fascicular pattern 
with varying cellularity and myointima-like fibromyxoid 
aggregates (so-called vascular balls). Mitotic activity is 
usually low or minimal, but mitotically active lesions may 
be encountered, particularly in so-called atypical IM [38]. 
IMs frequently exhibit a characteristic hemangiopericytoma-
like vascular pattern and may show extensive hyalinization 
or other regressive features, including hemorrhage, cystic 
degeneration, calcification, and even necrosis, which may 
give a false impression of malignancy. Tumor cells are often 
positive for vimentin and smooth muscle actin, but they are 
usually negative for desmin. S100, epithelial membrane anti-
gen, keratin, and vascular markers are absent in tumor cells 
[39]. All patients diagnosed with IM are recommended to be 
screened radiologically for multicentric disease and visceral 
involvement.
Outcome
IM may regress spontaneously, typically within 18 to 
24 months after diagnosis. Lesions may leave atrophic scars. 
Recurrences are possible. Visceral involvement is generally 
considered a poor prognostic feature. Mortality rates up to 
76–93%, often due to cardiopulmonary or gastrointestinal 
complications, were observed in published cohorts of 28 to 
31 children with multicentric disease with multiple visceral 
IM lesions [33, 36, 40]. Of note, aneurysms and fibromuscu-
lar dysplasia were reported in patients after a prior diagnosis 
of sporadic IM [15, 41–43]. A few children with sporadic 
IM were also reported to develop malignant tumors in addi-
tion to IM: fibrosarcomatous transformation of a congenital 
solitary IM was observed in a 14-months-old child [44]. Fea-
tures of high-grade malignancy were also seen in a recurrent 
lesion at the base of the tongue approximately 10 years after 
first diagnosis of a IM in the same area [45]. Metastatic 
rhabdomyosarcoma was diagnosed in a 2-year-old girl after 
spontaneous resolution of IM with visceral involvement 
[2]. A “neuroblastoma of the brainstem” was diagnosed in a 
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3-months-old child with a prior diagnosis of multicentric IM 
with orbital, facial, and intraoral lesions [46]. It is not clear 
if the malignant diagnoses in these anecdotal cases were 
confirmed by reference histology review or substantiated by 
further molecular analysis.
Treatment
Many patients diagnosed with IM have little or no symp-
toms. Disease progression is typically slow and local. A 
wait-and-see strategy is appropriate for many patients. If 
resection without sequelae appears feasible, solitary lesions 
may be removed surgically [2, 33, 35]. Patients with visceral 
involvement should be followed closely given the high risk 
of associated morbidity and mortality [33, 36, 40]. Systemic 
therapy is only recommended in case of life-threatening 
progressive disease, typically due to compression of vital 
structures or organ dysfunction in the setting of progressive 
visceral disease [35]. Vincristine/dactinomycin and vinblas-
tine/methotrexate regimens have been used with good results 
in patients with IM [35, 47]. Yet, similar to what has been 
observed in patients with aggressive fibromatosis [48–50], 
response to treatment tends to be slow. Alternatively, a few 
children with PDGFRB-mutated IM have been treated suc-
cessfully with imatinib and sunitinib [8, 15, 20, 28]. Prior 
to initiating systemic therapy, the acute and long-term side 
effects should always be considered carefully and weighed 
against the expected benefits.
Consensus recommendations
IM is a rare disease. The published literature is based on 
small cohorts [2, 34, 35]. The following recommendations 
summarize a review of the current literature and expert dis-
cussions within the SIOPE Host Genome Working Group.
Diagnosis
Prior to any biopsy or surgical intervention, it is impor-
tant to rule out fibrodysplasia ossificans progressiva (FOP, 
OMIM 135100), which is typically associated with an eas-
ily recognizable congenital valgus malformation of the big 
toes in affected infants [51]. FOP is a very rare condition 
caused by germline variants in the gene encoding activin A 
receptor type 1 (ACVR1) and is associated with progressive 
heterotopic extraskeletal ossification, which may present as 
tumor-like masses typically in the shoulder and back areas, 
on the scalp or head. Any type of soft tissue injury, including 
surgical removal or biopsy of soft-tissue lesions, may stimu-
late the development of new ossification foci. For all other 
children with a suspected diagnosis of IM, biopsy and veri-
fication of histopathology diagnosis by reference histology 
review is strongly recommended. All children diagnosed 
with IM (including solitary IM) should be screened for mul-
ticentric disease using whole body MRI and/or PET [52]. 
Cardiac lesions should be ruled out by cardiac ultrasound. 
Abdominal ultrasound, low-dose chest CT, skeletal surveys, 
and MRI of the brain may also be used to detect associated 
lesions [34]. For all patients with suspected IM, a careful 
family history covering three generations should be taken 
and specifically include history of small soft tissue nodules.
Genetic counseling and germline genetic testing
Genetic counseling and germline analyses of PDGFRB 
should be discussed with the parents of/offered to all chil-
dren diagnosed with IM and at least one of the following 
criteria: (i) multicentric manifestation, (ii) ≥ 1 first or sec-
ond degree relatives with IM or a history of soft tissue nod-
ules during childhood, (iii) a known causal or likely causal 
germline PDGFRB variant in the family, or (iv) suspected 
germline (mosaic) PDGFRB variants. Since the vast major-
ity of PDGFRB germline variants are located in exon 12, 
which encodes the juxtamembrane domain, Sanger or NGS 
sequencing of that exon would be appropriate in most cases 
and reduce the number of detected variants of uncertain sig-
nificance. However, it seems to be more realistic to get a 
virtually trimmed diagnostic PDGFRB (exon 12) sequencing 
result given the general switch to automated next-generation 
sequencing approaches technically covering gene panels, 
exomes, or even genomes. Predictive testing of relatives at 
risk can be offered to allow for identification of affected 
individuals and implement expert-based recommendations 
for surveillance during childhood.
Sequencing of PDGFRB in tumor tissue
IM has been associated with pathogenic variants in PDG-
FRB, which may confer sensitivity to tyrosine kinase inhibi-
tors such as imatinib. We recommend testing of IM tumor 
tissue for the presence of PDGFRB mutations by next-gener-
ation sequencing (NGS). Most variants map to exons 12 and 
14, suggesting that sequencing of these two hotspots may 
be sufficient in many cases. Nevertheless, up to one third of 
the reported pathogenic variants are located in other exons. 
Whenever possible, PDGFRB deep sequencing should be 
performed to increase sensitivity [7]. If disease is multicen-
tric and no mutation is detected in blood-derived DNA, we 
recommend testing at least three lesions (if possible) for the 
presence of PDGFRB mutations to screen for mosaicism.
Functional testing of PDGFRB variants
PDGFRB variants detected in IM tissue have been linked to 
sensitivity to tyrosine kinase inhibitors, including imatinib. 
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A list of imatinib-sensitive PDGFRB variants, previously 
detected in IM tissue, has been provided by Dachy et al [7]. 
Imatinib-sensitivity testing of other, new PDGFRB variants 
should be considered whenever possible.
Surveillance recommendations
IM presents mostly early in life and is generally associated 
with excellent outcomes. However, multicentric disease with 
visceral involvement, which is typically diagnosed in young 
infants, has a rather high mortality. Our review of the litera-
ture, indicates that IM risk in PDGFRB variant carriers is 
high, and many patients with familial IM are diagnosed with 
multicentric/generalized disease at birth or during infancy 
(Table 1). Additional features associated with PDGFRB ger-
mline variants include cerebral aneurysms. Knowledge of 
a family history of IM or familial PDGFRB variants may 
cause substantial anxiety.
Taking these considerations into account, patients with 
a first-degree relative with IM (solitary, multicentric or 
generalized) or a proven PDGFRB germline variant should 
undergo a baseline physical examination, abdominal and 
cardiac ultrasound after birth or following the detection of a 
causal familial PDGFRB germline variant. Follow-up clini-
cal evaluation, including a complete physical examination, 
evaluation of growth/weight gain, blood pressure measure-
ments and abdominal ultrasound, is recommended every 
3 months until the age of 24 months, then once every 1 to 
2 years until the age of 12 years. Any suspicious physical 
findings such as soft-tissue nodules, heart murmurs and fail-
ure to thrive should prompt further diagnostic evaluation, 
including whole body MRI and cardiac ultrasound (Table 2).
As PDGFRB germline variants associated with IM were 
recently also linked to the development of cerebral aneu-
rysms, a single MRI examination of the brain at the age 
of 15–18 years to screen for cerebral aneurysms can be 
considered.
Many patients with familial IM are diagnosed with multi-
centric or generalized disease during early infancy. Prenatal 
screening by ultrasound and, if there are any suspicious find-
ings, by prenatal MRI may be considered during the third 
trimester, if one parent carries a PDGFRB germline variant 
(typically p.Arg561Cys).
Research needs
We call for systematic registration of patients with IM to 
obtain a better understanding of the molecular underpin-
nings of IM and the course of disease and genotype–pheno-
type correlations.
Important clinical questions include:
(1) Prevalence of PDGFRB germline and somatic variants 
and PDGFRB mosaicism in children diagnosed with 
IM.
(2) Possible differences in IM penetrance in patients with 
different PDGFRB germline variants.
(3) Rate of visceral disease, life-threatening complications 
and death in patients with PDGFRB germline variants, 
PDGFRB somatic/mosaic variants and those without 
PDGFRB variants.
(4) Associated medical issues in PDGFRB germline vari-
ant carriers, including issues developing later in life, 
which may include aneurysms/fibromuscular dysplasia, 
malignant tumors, and neurological abnormalities.
Important biological questions include:
(1) Correlation of specific PDGFRB variants with imatinib 
sensitivity.
Table 2  Surveillance 
recommendations for 
individuals with a proven 
PDGFRB variant or first-degree 
relative with IM
Any suspicious physical findings such as soft-tissue nodules, heart murmurs and failure to thrive should 
prompt further diagnostic evaluation, including whole body MRI and cardiac ultrasound. Genetic coun-
seling should be offered to all patients/parents of patients with IM with a proven PDGFRB variant or a 
family history of IM
Age Surveillance recommendations Timing







Age 0–24 months Physical examination
Evaluation of growth/weight gain
Abdominal ultrasound
Every 3 months
Age 2–12 years Physical examination
Evaluation of growth/weight gain
Abdominal ultrasound
Yearly
Age 15–18 years MRI brain Once
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(2) Mechanism of development of somatic PDGFRB vari-
ants on the allele with the germline PDGFRB variant.
(3) Multicentric/generalized IM is generally considered a 
multifocal disorder. Metastases have anecdotally been 
reported in the past [53]. It is conceivable that certain 
lesions represent metastases rather than multiple inde-
pendent foci, but further clonality analyses/molecular 
testing are needed to understand the origins of multi-
centric disease.
(4) Pathogenicity of other, non-PDGFRB aberrations in 
IM.
(5) Potential overlap between myofibromas and myopericy-
tomas, benign perivascular tumors of pericytes, which 
bear close resemblance to myofibromas [32].
(6) Definition of the IM cell of origin.
Conclusions
IM is an extremely rare disease, which is typically diagnosed 
in young children and comprises a wide clinical spectrum 
ranging from solitary soft tissue nodules causing few symp-
toms to multiple disseminated tumors resulting in life-threat-
ening complications. Based on interdisciplinary discussions 
within the SIOPE Host Genome Working Group, we provide 
recommendations for somatic and germline genetic testing, 
genetic counselling, and surveillance. Close international 
and interdisciplinary collaboration is needed to improve our 
understanding of the clinical course and genetic underpin-
nings of IM and refine clinical practice recommendations.
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